Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 55 draft registration and review guidelines for Class II passive medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for non-powered equipment including radioactive seed implantation protective products.
Regulatory Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Center for Medical Device Evaluation (CMDE), National Medical Products Administration |
| Document | 55 Guiding Principles for Registration and Review of Class II Passive Medical Devices (Draft for Comments) |
| Lead guideline | Radioactive Seed Implantation Protective Products Registration and Review Guiding Principles |
| Total guidelines | 55 |
| Product class | Class II passive medical devices |
| Comment deadline | Oct 8, 2026 |
| Submission | Contact details per attached list |
Key Scope
The batch covers registration and review technical standards for 55 categories of Class II passive medical devices—equipment that does not rely on electrical energy or other power sources. The lead document addresses radioactive seed implantation protective products, with the full portfolio spanning diverse non-powered medical equipment categories used in surgical, therapeutic, and diagnostic settings.
Market Impact Analysis
The simultaneous release of 55 draft guidelines represents one of CMDE’s largest standardization efforts for mid-risk passive devices, creating a comprehensive regulatory roadmap for manufacturers navigating China’s Class II registration pathway. For domestic and international device makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, biocompatibility testing, and clinical evidence requirements.
The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II passive devices—a category that includes wound dressings, surgical instruments, infusion sets, and implantable accessories—signals intensified scrutiny of non-powered devices that are widely used across clinical settings but produced by a fragmented supplier base. The selection of radioactive seed implantation protective products as the lead guideline reflects growing regulatory attention to radiation oncology accessories as brachytherapy expands in China.
Forward-Looking Statement
Industry analysts expect the finalized 55 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II passive device registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new material testing protocols or sterilization validation requirements not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad device portfolios.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260901133559138.html